Trial Profile
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Malignant melanoma
- Focus Therapeutic Use
- 14 Feb 2021 Planned End Date changed from 1 Dec 2021 to 11 May 2020.
- 14 Feb 2021 Planned primary completion date changed from 1 Mar 2021 to 2 May 2020.
- 14 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.